A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
NCT06778863
This study is recruiting at 21 US sites in 13 states, according to its ClinicalTrials.gov record last updated .
Summary
Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Advanced Solid Tumor
- Unresectable Solid Tumor
- Metastatic Solid Tumor
- Colorectal Adenocarcinoma
- Pancreatic Adenocarcinoma
- Lung Cancer
- Ovarian Cancer
- Breast Cancer
- Head and Neck Squamous Cell Carcinoma
- Prostate Cancer
- Bladder Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Clasp Therapeutics, Inc.
- Last updated on ClinicalTrials.gov
- February 13, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 2
- HonorHealth Research Institute · Scottsdale, AZ
- The University of Arizona Cancer Center · Tucson, AZ
California · 3
- USC - Norris Comprehensive Cancer Center · Los Angeles, CA
- University of California Davis Comprehensive Cancer Center · Sacramento, CA
- University of California San Francisco · San Francisco, CA
Florida · 1
- University of Miami - Sylvester Comprehensive Cancer Center · Miami, FL
Illinois · 1
- The University of Chicago Comprehensive Cancer Center · Chicago, IL
Kentucky · 1
- University of Kentucky Markey Cancer Center · Lexington, KY
Maryland · 1
- Johns Hopkins - Sidney Kimmel Comprehensive Cancer Center · Baltimore, MD
New Jersey · 1
- Hackensack University Medical Center · Hackensack, NJ
New York · 2
- Memorial Sloan Kettering Cancer Center · New York, NY
- NYU Langone Health · New York, NY
North Carolina · 1
- Duke Cancer Institute · Durham, NC
Pennsylvania · 2
- Fox Chase Cancer Center · Philadelphia, PA
- Thomas Jefferson University, Sidney Kimmel Cancer Center · Philadelphia, PA
Tennessee · 2
- Sarah Cannon Research Institute (SCRI) Oncology Partners · Nashville, TN
- Vanderbilt University Medical Center · Nashville, TN
Texas · 3
- Baylor University Medical Center · Dallas, TX
- Mary Crowley Cancer Research · Dallas, TX
- MD Anderson Cancer Center · Houston, TX
Washington · 1
- Fred Hutchinson Cancer Center · Seattle, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.